Alkermes Plc (ALKS) stock news · P/E 108, rev $1.48B
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
This ALKS news page leads with what Alkermes Plc filed — not a scraped headline mill.
No cached 8-K sentence for ALKS yet. We will not pad this page with generic market recap.
Latest reported ALKS revenue for 2025-12-31 was $1.48B. Net income was $241.7M. Revenue was down 5.2% from 2024-12-31 to 2025-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 108.5.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the ALKS stock page; for the tape open the quote page.
ALKS stock news FAQ
What are ALKS's latest revenue and net income?
Latest cached Alkermes Plc (ALKS) revenue for Dec 31, 2025 was $1.48B. Net income was $241.7M. Statements: https://lician.com/financials/alks
How did ALKS revenue change from the prior cached period?
Cached Alkermes Plc (ALKS) revenue was down 5.2% from $1.56B (Dec 31, 2024) to $1.48B (Dec 31, 2025). Statements: https://lician.com/financials/alks
What is ALKS's P/E ratio?
Alkermes Plc (ALKS) trailing P/E is 108.5 on the latest cached fundamentals snapshot.
What is ALKS's market cap?
Alkermes Plc (ALKS) market cap is $4.78B on the latest cached fundamentals snapshot.
What kind of company is ALKS?
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
Where is ALKS stock news listed?
Cached stock news for Alkermes Plc (ALKS) is listed at https://lician.com/news/alks. Filings: https://lician.com/sec/alks
Not investment advice.